# A Single Ascending Dose Cohort Study of AG-73305 in DME Patients

> **NCT05301751** · PHASE2 · COMPLETED · sponsor: **Allgenesis Biotherapeutics Inc.** · enrollment: 25 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **BIOLOGICAL:** AG-73305

## Key facts

- **NCT ID:** NCT05301751
- **Lead sponsor:** Allgenesis Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-19
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-12-26
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05301751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05301751, "A Single Ascending Dose Cohort Study of AG-73305 in DME Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05301751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*